

David W Scott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2602991/publications.pdf>

Version: 2024-02-01

48
papers

6,236
citations

279798

23
h-index

289244

40
g-index

48
all docs

48
docs citations

48
times ranked

7166
citing authors

#	ARTICLE	IF	CITATIONS
1	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	1.6	824
2	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	16.8	706
3	A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. <i>Cancer Cell</i> , 2020, 37, 551-568.e14.	16.8	589
4	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	1.4	518
5	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
6	The tumour microenvironment in B cell lymphomas. <i>Nature Reviews Cancer</i> , 2014, 14, 517-534.	28.4	417
7	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. <i>Blood</i> , 2013, 122, 1256-1265.	1.4	349
8	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	1.6	334
9	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2016, 34, 3150-3156.	1.6	313
10	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-201.	1.6	257
11	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019, 9, 546-563.	9.4	213
12	Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2515-2526.	1.6	179
13	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132
14	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	1.4	112
15	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. <i>Nature Communications</i> , 2018, 9, 4001.	12.8	102
16	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2019, 134, 802-813.	1.4	96
17	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. <i>Blood</i> , 2019, 134, 761-764.	1.4	77
18	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	1.4	64

#	ARTICLE	IF	CITATIONS
19	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	1.6	60
20	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 203-214.	2.8	58
21	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2493-2500.	1.6	56
22	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	30.7	46
23	Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. <i>British Journal of Haematology</i> , 2017, 179, 508-510.	2.5	26
24	An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. <i>Blood</i> , 2015, 125, 959-966.	1.4	24
25	Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2021, 27, 1671-1680.	7.0	24
26	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. <i>British Journal of Haematology</i> , 2017, 176, 234-240.	2.5	20
27	Characterization of DLBCL with a PMBL gene expression signature. <i>Blood</i> , 2021, 138, 136-148.	1.4	19
28	Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 5401-5414.	7.0	16
29	Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	14
30	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	12
31	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. <i>Haematologica</i> , 2016, 101, e411-e414.	3.5	11
32	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	3.5	11
33	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	6.2	10
34	High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 481-484.	2.4	10
35	Validation of a simplified international prognostic score (IPS) in patients with advanced-stage classic Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 122-127.	2.5	9
36	Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 5285-5294.	5.2	7

#	ARTICLE	IF	CITATIONS
37	Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. British Journal of Haematology, 2022, 198, 684-692.	2.5	4
38	<i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. Cancer Discovery, 2021, 11, OF1-OF20.	9.4	2
39	Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach. Blood, 2019, 134, 2845-2845.	1.4	1
40	Outcome of elderly patients with classical Hodgkin lymphoma (HL) in British Columbia.. Journal of Clinical Oncology, 2020, 38, 8031-8031.	1.6	1
41	Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL. Cancer Discovery, 2021, 11, 2965-2967.	9.4	1
42	Impact of Disease Extent and Distribution on Outcomes in Stage II Follicular Lymphoma Treated with Curative-Intent Radiation Therapy. Blood, 2021, 138, 2431-2431.	1.4	0
43	Constrained FL: A Genetically Distinct Subgroup of Follicular Lymphoma with Low Rates of Somatic Hypermutation and a Reduced Propensity for Histologic Transformation. Blood, 2021, 138, 807-807.	1.4	0
44	Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada. Blood, 2020, 136, 13-15.	1.4	0
45	Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma. Blood, 2020, 136, 18-19.	1.4	0
46	Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC). Blood, 2020, 136, 33-34.	1.4	0
47	Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60. Cancers, 2022, 14, 908.	3.7	0
48	Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma. Leukemia and Lymphoma, 2022, 63, 2739-2742.	1.3	0